Atossa Therapeutics, Inc. (YAG2.SG)
- Previous Close
1.3320 - Open
1.3060 - Bid 1.2620 x --
- Ask 1.3000 x --
- Day's Range
1.2200 - 1.3060 - 52 Week Range
0.5380 - 1.9540 - Volume
2,000 - Avg. Volume
470 - Market Cap (intraday)
158.134M - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
atossatherapeutics.comRecent News: YAG2.SG
Performance Overview: YAG2.SG
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YAG2.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YAG2.SG
Valuation Measures
Market Cap
166.19M
Enterprise Value
83.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.84%
Return on Equity (ttm)
-28.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.09M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
88.46M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.76M